TwitterLinkedIn

Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers

By |2020-12-15T16:52:47+00:00December 15th, 2020|

Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers Dec 15, 2020, 07:00 ET Read on Cision PR Newswire LP-184 preclinical studies reinforce the drug compound’s potential to effectively cross the blood-brain barrier with significant potency Continued progress in advancing glioblastoma [...]

> Read More

Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging Agent

By |2020-10-05T15:46:33+00:00October 5th, 2020|

Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging AgentOct 05, 2020, 07:46 ETRead on Cision PR NewswireDALLAS, Oct. 5, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug discovery and development, and identify patients who will benefit [...]

> Read More
© Copyright 2020 Lantern Pharma, Inc.  |   ALL RIGHTS RESERVED   |   
TwitterLinkedIn
Lantern Pharma, Inc. informs you that our website uses its own and third party cookies to improve our services and collect statistical information about your browsing. By clicking accept, we consider that you accept its use. For more information, or to know how to change the configuration, consult our Privacy Policy. I Accept